SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
A contemporary artistic collage featuring a hand holding a trophy. The concept of victory and achievement.
Autoimmune disease
MaaT Clears Phase III in GVHD, Eyes European Submission By Midyear
MaaT013 in 2022 was put under clinical hold by the FDA, which cited safety and efficacy concerns with the sample-pooling method used to produce the investigational therapy. The hold was lifted in April 2023.
January 9, 2025
 · 
2 min read
 · 
Tristan Manalac
Trendy halftone business concept collage. Idea concept, business concept, financial planning,financial profit, favorable conditions, favorable conditions. Trendy modern retro illustration in bright trendy colors. Vector illustration
Startups
Verdiva Jumps Into Hot Obesity Market With $410M Debut, Eyes Next-Gen Therapies
The company’s lead asset is a potentially first-in-class oral GLP-1 receptor agonist that has the potential to be dosed weekly, which according to CEO Khurem Farooq can help improve accessibility and affordability.
January 9, 2025
 · 
2 min read
 · 
Tristan Manalac
FDA signage at its headquarters in Maryland
Regulatory
After Drug Rejection, Vanda Blasts ‘Unacceptable’ FDA Conduct in Letter to Commissioner
Vanda called the attention of FDA Commissioner Robert Califf to what it termed the “sentiment that the agency avoids public scrutiny of its decisions.”
January 9, 2025
 · 
2 min read
 · 
Tristan Manalac
Lilly Institute for Genetic Medicine building in Boston, Ma, USA, on November 11, 2023. Eli Lilly and Company is an American pharmaceutical company.
Government
Lilly Wins Medicare Coverage for Zepbound in Sleep Apnea
According to BMO Capital Markets, Medicare coverage of Lilly’s Zepbound opens the door to using secondary indications to secure CMS coverage for obesity drugs.
January 9, 2025
 · 
2 min read
 · 
Tristan Manalac
Illustration of employer’s hand holding employee who was laid off to drop him out of office
Layoffs
From Bad to Worse: 3 Ways Biopharmas Make Layoffs More Painful for Employees
Being laid off is bad enough. When companies mishandle the layoff process, it can make the situation even worse. Four biopharma professionals share how some employers are getting it wrong.
January 9, 2025
 · 
5 min read
 · 
Angela Gabriel
Contemporary art collage. Purple hand holding fan of dollar bills against bright yellow background. stock photo
Deals
Biopharma Finishes 2024 Strong With ‘Robust’ VC, Upfront Payments: JP Morgan
J.P. Morgan releases its quarterly look-ahead days before the entire biopharma industry descends on San Francisco for the annual J.P. Morgan Healthcare Conference.
January 9, 2025
 · 
3 min read
 · 
Annalee Armstrong
Banner. Contemporary art collage. Charity or alms. Person handing single coin to another person. Grainy fabric effect. Concept of business, financial literacy, debts, banking, salary. Ad
Neuroscience
Tenvie Debuts With Denali Assets, $200M for Neurological, Metabolic Diseases
Backed by ARCH Venture Partners, F-Prime Capital and Mubadala Capital, the new company will develop a pipeline of brain-penetrant small molecules to address inflammation, metabolic dysfunction and restoring lysosomal function.
January 8, 2025
 · 
1 min read
 · 
Annalee Armstrong
Roche's signage at its office in France
Mergers & acquisitions
Roche Nears Completion of Poseida Acquisition Worth Up to $1.5B
In a deal expected to close in Q1 2025, Roche will gain access to Poseida’s off-the-shelf CAR T candidates.
January 8, 2025
 · 
3 min read
 · 
Tristan Manalac
Correct decision chosing - confused man character standing on the crossroads and looking at signpost with three different directions - conceptual vector illustration
Cell therapy
Galapagos to Spin Out Innovative Medicines, Lay Off 40%
By mid-2025, the biotech will split into two entities: a new, as-yet-unnamed innovative medicines specialist and a cell therapy company, the latter of which will inherit the Galapagos name.
January 8, 2025
 · 
3 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS